publication date: Jan. 31, 2014


ACS, SU2C Committ $20 Million For Lung Cancer Dream Team

The American Cancer Society and Stand Up To Cancer announced a collaboration to fund translational research and advocacy programs.

The collaboration’s first project will be a three-year, $20 million research Dream Team focused on developing new therapies for lung cancer. ACS and SU2C will split funding equally. Bristol-Myers Squibb will also provide $5 million to support the dream team.

“This alliance marries the society’s comprehensive cancer-fighting mission with SU2C’s high-impact funding model,” ACS CEO John Seffrin said in a statement.

“Lung cancer is the leading cause of cancer mortality in the United States,” said Phillip Sharp, Nobel laureate and institute professor at the Massachusetts Institute of Technology and Koch Institute for Integrative Cancer Research, who is chairman of SU2C’s Scientific Advisory Committee. “More work is urgently needed to address the many unanswered questions about lung cancer and guide new directions in treatment.”

The collaboration will also include an advocacy component, led by the American Cancer Society Cancer Action Network and SU2C.

Later this year, the American Association for Cancer Research, SU2C’s scientific partner, will issue a call for research proposals. The selection process will be conducted by a joint scientific advisory committee composed of an equal number of experts nominated by SU2C and ACS. The team itself will be announced in 2015.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.